Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.
Lopez-Albaitero A, Xu H, Guo H, Wang L, Wu Z, Tran H, Chandarlapaty S, Scaltriti M, Janjigian Y, de Stanchina E, Cheung NK.
Lopez-Albaitero A, et al.
Oncoimmunology. 2017 Mar 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017.
Oncoimmunology. 2017.
PMID: 28405494
Free PMC article.